Key facts
- It has raised $27.0M; the latest was Early Stage VC ($20.0M) in Dec 2025.
- Notable investors include GV, SignalFire, Virtue (Austin), McKesson Ventures, Iaso Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Prudentia Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Prudentia Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Prudentia Sciences
Developer of drug development platform intended to support AI-powered Asset Diligence and Valuation to De-Risk Investment. The company's platform offers a drug asset marketplace to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact, allowing investors and biopharma clients to effectively position and showcase asset value during portfolio strategy planning and dealmaking.
- Sector
- Information Technology
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 14
- Website
- prudentiasciences.com/
- Ownership
- Privately Held (backing)
Prudentia Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prudentia Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prudentia Sciences in its N-PORT filings yet. We sweep new filings monthly.